Skip to main content
BMC Women's Health logoLink to BMC Women's Health
. 2021 Jan 6;21:13. doi: 10.1186/s12905-020-01160-w

Menstrual, reproductive and hormonal factors and thyroid cancer: a hospital-based case–control study in China

Meng Wang 1,#, Wei-Wei Gong 1,#, Qing-Fang He 1, Ru-Ying Hu 1, Min Yu 1,
PMCID: PMC7789638  PMID: 33407401

Abstract

Background

There have been considerable studies on the effects of reproductive factors on thyroid cancer risk, while findings are inconsistent. In this analysis, we aimed to investigate the associations between menstrual, reproductive and hormonal factors with thyroid cancer occurrence in a population of Chinese women.

Methods

Using data from a 1:1 matched case–control study performed between 2015 and 2017 in Zhejiang Province of China, a second analysis of 2261 pairs of female subjects was conducted. The possible effects for thyroid cancer were evaluated in logistic regression models by odds ratios (ORs) with 95% confidence intervals (CIs).

Results

Later age at first pregnancy (for > 25 vs. ≦ 20 years, OR: 0.47, 95% CI 0.23–0.96) and longer duration of breast feeding (for 6–12 vs. ≦ 6 months, OR: 0.49, 95% CI 0.24–0.98) were significantly associated with decreased occurrence of thyroid cancer, while no trend was observed. Stratified by age at enrollment, only the association with duration of breast feeding remained significant, but limited to younger women (≦ 50 years).

Conclusions

Our results suggested that women with later age at first pregnancy or longer breast feeding duration were less likely to have thyroid cancer. These findings supported an influence role of reproductive factors in thyroid cancer risk.

Keywords: Reproductive history, Pregnancy, Thyroid cancer, Case–control study

Background

Thyroid cancer is the most common cancer of the endocrine system [1] and the incidence has been increasing worldwide for the last decades [2]. In China, between 2000 and 2011, a dramatic rise in thyroid cancer incidence was observed among national female population, with an annual percentage change (APC) of 20.1% [3]. The rise in incidence may be attributed to the improved diagnostic techniques and over diagnosis in certain parts of the world [4, 5]. However, in 2017, the American College of Radiology (ACR) committees has published the Thyroid Imaging, Reporting and Data System (TI-RADS) guidelines to provide guidance regarding management of thyroid nodules on the basis of their ultrasound appearance [6]. Thus, a true increase in incidence also exists, which could be due to elevated exposure risks [7, 8].

Epidemiological research has identified ionizing radiation and benign thyroid disease as established risk factors for thyroid cancer [9]. Some other environmental and lifestyle factors, such as high body mass index (BMI), as well as low or high iodine intake and sleep disturbance were also reported [5, 10, 11]. However, in actual, the etiology of thyroid cancer remains largely unknown. It has long been suggested that the thyroid cancer incidence is much higher in women than in men [3, 12]. Furthermore, previous studies showed that the female-to-male incidence ratio is found to be the largest during the years between menarche and menopause [13], which support an influence role of menstrual, reproductive or hormonal factors in the etiology of thyroid cancer. To further confirm the hypothesis, considerable studies with different design have been conducted on this topic, while the observations were weak and inconsistent [1416]. Besides, the above evidence was mainly from western world and other Asia counties, but limited studies were seen among Chinese female population. Between 2015 and 2017, we conducted a hospital-based case–control study in Zhejiang Province to explore the associated factors for thyroid cancer. In the study, self-reported data on menstrual, reproductive, and hormonal factors were collected, which provided us an opportunity to investigate the associations with thyroid cancer in Chinese women.

Methods

Study subjects

To explore the associations of diabetes mellitus and other factors with thyroid cancer, a 1:1 matched hospital-based case–control study was performed in 7 counties (Lucheng, Pingyang, Cangnan, Cixi, Nanhu, Changxing and Yongkang) of Zhejiang Province. Case subjects were eligible if they were first primary thyroid cancer diagnosed in hospitals from July 2015 to December 2017. All the cases were identified by physician review of medical records and pathology reports. Notably, among the cases, those who had a history of any cancer or were unable/unwilling to complete the study questionnaire were excluded. In the current study, thyroid cancer was further identified based on ICD-10 and referred to malignant neoplasm of thyroid gland (C73). In the same area and same year, control subjects were selected from thyroid-healthy examinees who underwent thyroid function tests and thyroid ultrasound screening in the annual routine physical examination, which was conducted in local hospitals. In Zhejiang Province, authorized by the government, fixed local hospitals will organize physical examination covering all the insured residents in community or village once a year. We excluded subjects with abnormal levels of free triiodothyronine, free thyroxine, and thyroid stimulating hormone (TSH), respectively. Besides, we excluded those whose ultrasound findings were suspicious for malignancy. Control subjects who had a history of any cancer or were unable/unwilling to complete the study questionnaire were also excluded. Finally, case subjects were matched to control subjects by age (plus or minus three years) and sex with 1:1.

Estimation of the sample size

In our study, the cases and controls were selected by 1:1, so we calculated the sample size with the following special formula.

M=m/(p0q1+p1q0)

Among them,

m=Uα/2+Uβp(1-p)2/p-122
p=OR/(1+OR)RR/(1+RR)
p1=p0OR1+p0(OR-1)
q1=1-p1,q0=1-p0

P0: The estimated diabetes exposure rate in control group; P1: The estimated diabetes exposure rate in case group; We presumed that: P0 = 0.07, OR = 2, α = 0.05, β = 0.10.

Consequently, M = 398 in each county, and actually, 2937 pairs of subjects were recruited in 7 counties.

Questionnaire

With a designed questionnaire (Additional file 1), the interviewer collected all relevant information face-to-face at enrollment. The questionnaire was completed within two months after each pair of case and control was successfully matched. The questionnaire design went through literature review, panel discussion, check and approval by experts and revision after pilot study. Especially, to obtain the relatively high reliability of the questionnaire, we have reviewed literature and discussed in panel about the setting of questions. Besides, using the Delphi method, we invited relevant experts to check and revise the questionnaire. Finally, we also conducted several rounds of pilot studies to make sure the test–retest reliability was high. The same structured questionnaire was administered to each pair of subjects by the same trained interviewer. The questionnaire was used to collect the information on socio-demographic characteristics, individual history and family history of chronic diseases, lifestyle behaviors, environmental hazardous substances exposure, and dietary habits, etc. The present investigation focused on menstrual, reproductive and hormonal factors, including age at menarche, regularity of menstrual cycle, dysmenorrheal history, age at menopause, number of pregnancies, age at first/last pregnancy, outcome of the first pregnancy, breast feeding duration, use of oral contraceptives, hormone therapy, and history of hysterectomy and oophorectomy.

Statistical analysis

Descriptive statistics were used to describe the baseline characteristics of female subjects with frequency and proportion. Univariate conditional logistic regression models were performed to examine the relationships of the covariates with the thyroid cancer.

To examine the associations between menstrual, reproductive and hormonal factors with thyroid cancer, we conducted four multivariable conditional logistic regression models to adjust for the covariates, including age (continuous), education level (no formal/primary school, middle/high school, college/university/postgraduate), average monthly household income (≦ 2000, 2000–5000, > 5000 Yuan), marriage status (unmarried, married), history of goiter (yes, no), history of nodules (yes, no), alcohol drinking (never, occasional, current regular), and BMI. Notably, BMI (kg/m2) was calculated as weight divided by the square of height. According to the Chinese adult BMI classification proposed by the Working Group on Obesity in China in 2001 [17], subjects were categorized as underweight (< 18.5), normal weight (18.5–23.9), overweight (24.0–27.9), and obesity (≥ 28.0). The possible effects were showed with odds ratios (ORs) and their 95% confidence intervals (CIs). In model 1, only age (continuous) was adjusted. In model 2, age (continuous) and other socio-demographic characteristics including education level, average monthly household income, marriage status, and history of goiter and nodules were included. Model 3 adjusted for model 2 plus the health behavior of alcohol intake. Model 4 adjusted for model 3 plus BMI. In model 4, the tests for trend were calculated using linear-by-linear association chi square test. Subgroup analyses were performed stratified by age (≦ 50, > 50 years) in multivariable logistic regression models and only the final results (model 4) were showed. All analyses were based on the two-sided 5% level of significance and performed using SAS statistical package (version 9.2, SAS Institute, Inc., Cary, NC, USA).

Results

A total of 2937 pairs of subjects participated in the case–control study. Among them, there were 2261 pairs (77.0%) of females. In the present study, based on the study purposes, only the female subjects were available in the analysis process. Among the 2261 thyroid cancer cases, there were 2074 papillary cancers, 72 follicular cancers, 13 medullary cancers, 16 undifferentiated cancers and 86 other type. The mean age in female case and control subjects was 49.44 ± 1.16 years and 49.32 ± 1.18 years, respectively. Frequencies and proportions of baseline characteristics among case and control subjects were showed in Table 1. Compared to control subjects, case subjects were more likely to be overweight (P = 0.002), have goiter (P < 0.001) and nodules (P < 0.001) and less likely to be underweight (P = 0.012), have higher household income (> 5000 Yuan, P = 0.001), intake alcohol occasionally (P < 0.001) and current regularly (P = 0.013).

Table 1.

The baseline characteristics of female subjects and their relationships with thyroid cancer

Factors Cases (N = 2261; %) Controls
(N = 2261; %)
P OR 95% CI
Age (Years) 49.44 ± 1.16 49.32 ± 1.18 Matched
Education level
 No formal/primary school 985 (43.56) 968 (42.81) Ref
 Middle/high school 913 (40.38) 904 (39.98) 0.658 0.96 0.82–1.13
 College/university/postgraduate 359 (15.88) 384 (16.98) 0.136 0.82 0.64–1.06
Marriage status
 Unmarried 105 (4.64) 91 (4.02) Ref
 Married 2151 (95.13) 2170 (95.98) 0.163 0.75 0.51–1.12
Average monthly household income (Yuan)
  ≤ 2000 1646 (72.80) 1598 (70.68) Ref
 2000–5000 271 (11.99) 242 (10.70) 0.947 1.01 0.81–1.25
  > 5000 341 (15.08) 415 (18.35) 0.001 0.69 0.55–0.85
Body mass index (kg/m2)
 Normal weight (18.5–23.9) 1298 (57.41) 1416 (62.63) Ref
 Underweight (< 18.5) 79 (3.49) 122 (5.40) 0.012 0.67 0.49–0.91
 Overweight (24.0–27.9) 652 (28.84) 581 (25.70) 0.002 1.26 1.09–1.45
 Obese (≥ 28.0) 157 (6.94) 142 (6.28) 0.073 1.25 0.98–1.59
Alcohol category
 Never 1848 (81.73) 1670 (73.86) Ref
 Occasional 337 (14.90) 495 (21.89)  < 0.001 0.55 0.47–0.66
 Current regular 76 (3.36) 96 (4.25) 0.013 0.66 0.48–0.92
History of goiter
 No 1346 (59.53) 633 (28.00) Ref
 Yes 181 (8.01) 19 (0.84)  < 0.001 8.67 3.72–20.18
History of nodules
 No 1175 (51.97) 555 (24.55) Ref
 Yes 352 (15.57) 96 (4.25)  < 0.001 2.35 1.66–3.32

OR odds ratio, CI confidence interval, Ref. reference

Percentages of each variable may not equal 100 because of missing data or rounding

Table 2 showed the results of multivariable models investigating the associations between menstrual, reproductive and hormonal factors with thyroid cancer. In model 1, longer breast feeding duration of 6–12 months and > 12 months were significantly associated with decreased occurrence of thyroid cancer, with the ORs were 0.69 (95% CI 0.55–0.88) and 0.68 (95% CI 0.52–0.90), respectively. Women with hormone therapy use (OR: 2.16, 95% CI 1.13–4.14) and hysterectomy (OR: 1.71, 95% CI 1.19–2.46) were more likely to have thyroid cancer. With further adjustment for other socio-demographic characteristics and health behavior of alcohol, both later age at menarche (≥ 17 vs. 13–14 years) and age at first pregnancy (> 25 vs. ≦ 20 years) were significantly associated with decreased occurrence of thyroid cancer in model 2 and 3. After adjustment for the BMI in model 4, women with later age at first pregnancy (> 25 vs. ≦ 20 years) and relatively longer duration of breast feeding (6–12 vs. ≦ 6 months) were less likely to have thyroid cancer, with the ORs were 0.47 (95% CI 0.23–0.96) and 0.49 (95% CI 0.24–0.98), respectively. In the final results, no trend was observed (all P-values > 0.05). Stratified analyses showed that the associations between menstrual, reproductive and hormonal factors with thyroid cancer were modified by age, and no interactions were found (all P-values > 0.05). The specific results were showed in Additional file 2: Table S1.

Table 2.

ORs of thyroid cancer associated with menstrual, reproductive and hormonal factors

Factors Cases
(N = 2261)
Controls (N = 2261) Model 1 Model 2 Model 3 Model 4
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Menstrual factors
Age at menarche (years)
 ≦ 12 104 99 0.51 0.23–1.12 0.72 0.18–2.92 0.77 0.19–3.17 0.67 0.15–3.10
 13–14 974 995 Ref Ref Ref Ref
 15–16 857 859 0.90 0.69–1.18 0.73 0.46–1.17 0.72 0.45–1.16 0.79 0.48–1.30
  ≥ 17 304 290 0.85 0.61–1.19 0.54 0.29–0.99 0.52 0.28–0.97 0.59 0.31–1.12
 P for trend 0.650
Had regular menstrual cycles
 No 187 182 1.27 0.82–1.96 0.66 0.32–1.40 0.63 0.30–1.34 0.61 0.28–1.35
 Yes 2054 2067 Ref Ref Ref Ref
Had dysmenorrhea
 No 1757 1719 Ref Ref Ref Ref
 Yes 495 535 0.92 0.70–1.21 0.82 0.51–1.32 0.81 0.50–1.31 0.70 0.42–1.18
Age at menopause (years)
 ≦ 44 68 64 0.97 0.60–1.58 1.08 0.49–2.39 1.03 0.46–2.30 0.98 0.42–2.29
 45–49 249 224 1.03 0.77–1.39 0.98 0.57–1.67 0.96 0.56–1.65 0.92 0.52–1.61
 50–51 307 315 Ref Ref Ref Ref
 ≥ 52 307 303 1.07 0.82–1.39 0.90 0.57–1.41 0.86 0.54–1.36 0.89 0.55–1.44
 P for trend 0.496
Reproductive factors
Number of pregnancy
 1 613 631 Ref Ref Ref Ref
 2 771 796 0.96 0.77–1.18 0.63 0.36–1.12 0.62 0.35–1.11 0.67 0.37–1.23
  ≥ 3 774 728 1.04 0.81–1.34 0.64 0.34–1.20 0.62 0.33–1.18 0.66 0.34–1.28
 P for trend 0.222
Age at first pregnancy (years)
 ≦ 20 336 325 Ref Ref Ref Ref
 20–25 1387 1354 0.99 0.78–1.25 1.03 0.63–1.69 1.03 0.63–1.70 0.96 0.57–1.61
 > 25 426 465 0.87 0.64–1.19 0.47 0.24–0.93 0.47 0.23–0.94 0.47 0.23–0.96
 P for trend 0.200
Outcome of the first pregnancy
 Live birth 1920 1946 Ref Ref Ref Ref
 Miscarriage 81 80 1.13 0.78–1.64 0.93 0.37–2.33 0.94 0.37–2.35 0.85 0.33–2.20
 Abortion 125 95 1.39 0.99–1.96 0.81 0.31–2.07 0.78 0.30–2.03 0.80 0.30–2.09
 Stillbirth or ectopic 22 18 1.28 0.65–2.53 1.36 0.34–5.53 1.37 0.34–5.57 1.37 0.33–5.62
Age at last pregnancy (years)
 ≦ 25 806 777 Ref Ref Ref Ref
 25–30 883 924 0.97 0.81–1.17 1.17 0.76–1.81 1.17 0.75–1.81 1.21 0.77–1.90
 > 30 418 409 1.04 0.81–1.33 1.54 0.86–2.76 1.50 0.83–2.73 1.63 0.88–3.00
 P for trend 0.667
Duration of breast feeding (months)
 ≦ 6 293 234 Ref Ref Ref Ref
 6–12 1040 1087 0.69 0.55–0.88 0.52 0.26–1.03 0.53 0.27–1.05 0.49 0.24–0.98
 > 12 674 685 0.68 0.52–0.90 0.67 0.31–1.44 0.68 0.31–1.46 0.60 0.27–1.31
 P for trend 0.090
Hormonal factors
Oral contraceptive use
 No 1637 1667 Ref Ref Ref Ref
 Yes 62 56 0.96 0.63–1.46 1.24 0.51–3.03 1.17 0.48–2.87 1.18 0.47–2.96
Hormone therapy use
 No 2204 2233 Ref Ref Ref Ref
 Yes 57 28 2.16 1.13–4.14 2.24 0.53–9.56 2.06 0.47–9.06 1.47 0.30–7.38
Hysterectomy and oophorectomy status
 None 2107 2162 Ref Ref Ref Ref
 Hysterectomy alone 119 74 1.71 1.19–2.46 1.36 0.74–2.52 1.37 0.74–2.54 1.45 0.77–2.73
 Oophorectomy alone 28 15 2.01 0.93–4.34 1.84 0.42–7.96 1.74 0.41–7.41 1.93 0.43–8.72
 Hysterectomy and oophorectomy 7 10 1.19 0.36–3.97 4.60 0.51–41.45 4.67 0.52–41.98 3.85 0.43–34.59

Trend test was calculated using the linear-by-linear association chi square test

OR odds ratio, CI confidence interval, Ref. reference

Bold numbers represent significant results

Model 1 only adjusted for age (continuous); Model 2 adjusted for model 1 plus socio-demographic characteristics including education level, average monthly household income, marriage status, and history of goiter and nodules; Model 3 adjusted for model 2 plus the health behavior of alcohol intake; Model 4 adjusted for model 3 plus body mass index

Discussion

In this case–control study, we investigated the associations between numerous menstrual, reproductive and hormonal factors with thyroid cancer occurrence in Chinese female population. According to the analyses, our results suggested decreased occurrence of thyroid cancer among women who reported a later age at first pregnancy or longer duration of breast feeding, although no trend was observed. In the stratified analysis by age at enrollment, differences in this pattern were noted, where the effects of age at first pregnancy diminished to be null and only the association with duration of breast feeding remained significant in younger women.

In the present study, later age at first pregnancy was significantly associated with lower occurrence of thyroid cancer in total women (for > 25 vs. ≦ 20 years, OR: 0.47, 95% CI 0.23–0.96), whereas the association was not significant in age subgroups (≦ 50 and > 50 years). In contrast, a population-based case–control study of young women below age 35 years performed in France reported a lower risk of thyroid cancer among those who had a first pregnancy after the age of 25 years (OR: 0.5, 95% CI 0.3–0.9) [18]. Several other studies on this topic have also been conducted, giving mixed results. A meta-analysis of prospective studies showed a directly opposite result that the increasing age at first pregnancy/birth was positively associated with thyroid cancer risk (SRR: 1.56, 95% CI 1.01–2.42) [19]. Parallel to this, findings from a population-based case–control study conducted in San Francisco Bay Area suggested an increase in risk with age at first full term pregnancy between 25 and 29 years (OR: 3.3, 95% CI 1.5–7.4) and ≥ 30 years (OR: 2.8, 95% CI 1.1–7.0), with reference to < 20 years, but these associations were restricted to younger women (< 45 years) [13]. Meanwhile, in some other studies have investigated this relationship of age at first pregnancy with thyroid cancer, non-significant higher or lower risks were also observed [20, 21]. As in the age at first pregnancy, the relationships between duration of breast feeding and thyroid cancer risk seemed to be inconclusive as well. In this study, we found decreased occurrence of thyroid cancer among women with relatively longer duration of breast feeding (for 6–12 vs. ≦ 6 months, OR: 0.49, 95% CI 0.24–0.98). Consistently, pooled result from a recent meta-analysis of cohort studies suggested that longer duration of breast feeding was associated with moderately decreased risk of thyroid cancer (RR: 0.7, 95% CI 0.51–0.95) [22]. Similar results concerning the protective effect of breast feeding was also confirmed in a case–control study conducted in France (OR per month: 0.7, 95% CI 0.5–1.0) [18]. However, a few other studies found little support for the association of breast feeding duration with risk of developing thyroid cancer [2225]. Besides, it is noteworthy that, in a population-based case–control study conducted in western Washington State, the authors brought the recency of breast feeding into analysis and found that the risk was increased among parous women with breast feeding during the previous 5 years (for ≥ 12 vs. 0–1 months, RR: 2.9, 95% CI 1.5–5.5) [26]. In theory, the major differences in the associations of age at first pregnancy and breast feeding with thyroid cancer among published studies with respect to sample size, study design, population characteristics, definition and categorization of the exposures of interest. Based on previous studies, the potential mechanism behind the associations of later age at first pregnancy and longer breastfeeding duration with lower thyroid cancer risk might be the decreased level of estrogens, which could have a function in the proliferation of malignant thyroid cells [18, 27, 28]. In the current study, the absence of significant results across the majority of menstrual, reproductive and hormonal factors provided little support for their associations with thyroid cancer. Nevertheless, the lack of appreciable relationships with age at menarche and menopause, miscarriage and abortion or oral contraceptive and hormonal therapy use were also of importance, since they have been extensively investigated in previous studies [2931].

Strengths of our study included relatively large number of women, all diagnosed incident thyroid cancer cases identified by physician in hospital and the availability of a range of menstrual, reproductive and hormonal factors.

However, some limitations should be considered. Firstly, the detailed information on exposures of interest was reported by women themselves and the recall bias inherent to case–control studies may be inevitable. Secondly, the lack of some information on the exposures, such as the menopausal status, recency of breast feeding, the type and duration of oral contraceptive and hormone therapy use, limited our ability to investigate their associations with thyroid cancer risks in depth. Thirdly, despite adjustment for a certain set of confounders, other potential risk factors for thyroid cancer may have affected the final results.

Conclusions

In conclusion, our results suggested that later age at first pregnancy and longer breast feeding duration were significantly associated with the decreased occurrence of thyroid cancer, which might shed light on the etiology, monitoring and prevention of thyroid cancer among Chinese women. However, further evidence from prospective studies on the possible influence role of menstrual, as well as reproductive and hormonal factors in the risk of thyroid cancer among Chinese female population is warranted.

Supplementary information

12905_2020_1160_MOESM1_ESM.docx (79.8KB, docx)

Additional file 1. The questionnaire used for this study.

12905_2020_1160_MOESM2_ESM.docx (20KB, docx)

Additional file 2: Table S1. ORs of thyroid cancer associated with menstrual, reproductive and hormonal factors, stratified by age at enrollment.

Acknowledgements

We thank the all colleagues at hospitals, health services centers, and CDCs participated in the study for their important contributions.

Abbreviations

APC

Annual percentage change

BMI

Body mass index

TSH

Thyroid stimulating hormone

OR

Odds ratio

CI

Confidence interval

Authors' contributions

MW designed the study. WWG collected, analyzed the data with QFH. Professors RYH and MY gave much advice and directions in both study design and preparing of the manuscript. All the authors have read and approved the final submitted version.

Funding

This work was supported by grant from the National Key Research and Development Program of China “precision medical research” (2016YFC0900502) from the Ministry of Science and Technology; grant from Zhejiang Medical and Health Technology Project (2021KY614). The study sponsors contributed to study design but had no role in the collection, analysis, and interpretation of data; the writing of the paper; or the decision to submit the paper for publication.

Availability of data and materials

The data can be accessed from the corresponding author upon justified request.

Ethics approval and consent to participate

This study was carried out in accord with the “Declaration of Helsinki” and the verbal consents were obtained from participants and approved by the Ethics Committee of Zhejiang Provincial Center for Disease Control and Prevention (CDC). The ethics committee approved the procedure for verbal consent because Zhejiang CDC has the authority of the Zhejiang provincial government to collect the cancer cases and related information, which is part of disease surveillance scope in Zhejiang CDC. All the participants (cases and controls) were notified that they have the right to refuse or terminate the study at any point of the interview. Because we obtained verbal consent, documentation of consent was not required. However, the information provided by each participant was kept confidential in Zhejiang CDC.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Meng Wang and Wei-Wei Gong have contributed to the article equally.

Contributor Information

Meng Wang, Email: mwang@cdc.zj.cn.

Wei-Wei Gong, Email: wwgong@cdc.zj.cn.

Qing-Fang He, Email: qfhe@cdc.zj.cn.

Ru-Ying Hu, Email: ryhu1234@163.com.

Min Yu, Email: mycdc1234@163.com.

Supplementary information

The online version contains supplementary material available at 10.1186/s12905-020-01160-w.

References

  • 1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
  • 2.Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, Global Burden of Disease Cancer Collaboration et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527. doi: 10.1001/jamaoncol.2015.0735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. [DOI] [PubMed] [Google Scholar]
  • 4.Ahn HS, Welch HG. South Korea's Thyroid-Cancer "Epidemic"–Turning the Tide. N Engl J Med. 2015;373:2389–2390. doi: 10.1056/NEJMc1507622. [DOI] [PubMed] [Google Scholar]
  • 5.Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic review of trends in the incidence rates of thyroid cancer. Thyroid. 2016;26:1541–1552. doi: 10.1089/thy.2016.0100. [DOI] [PubMed] [Google Scholar]
  • 6.Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587–595. doi: 10.1016/j.jacr.2017.01.046. [DOI] [PubMed] [Google Scholar]
  • 7.Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16:17–29. doi: 10.1038/s41574-019-0263-x. [DOI] [PubMed] [Google Scholar]
  • 8.Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–1348. doi: 10.1001/jama.2017.2719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 2013;63:374–394. doi: 10.3322/caac.21195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kitahara CM, McCullough ML, Franceschi S, Rinaldi S, Wolk A, Neta G, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid. 2016;26:306–318. doi: 10.1089/thy.2015.0319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Luo J, Sands M, Wactawski-Wende J, Song Y, Margolis KL. Sleep disturbance and incidence of thyroid cancer in postmenopausal women the Women's Health Initiative. Am J Epidemiol. 2013;177(1):42–49. doi: 10.1093/aje/kws193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–2195. doi: 10.1002/ijc.29251. [DOI] [PubMed] [Google Scholar]
  • 13.Sakoda LC, Horn-Ross PL. Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomark Prev. 2002;11:51–57. doi: 10.1002/ijc.29251. [DOI] [PubMed] [Google Scholar]
  • 14.Peterson E, De P, Nuttall R. BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS ONE. 2012;7:e29177. doi: 10.1371/journal.pone.0029177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mannathazhathu AS, George PS, Sudhakaran S, Vasudevan D, Krishna Km J, Booth C, et al. Reproductive factors and thyroid cancer risk: meta-analysis. Head Neck. 2019;41:4199–4208. doi: 10.1002/hed.25945. [DOI] [PubMed] [Google Scholar]
  • 16.Wang P, Lv L, Qi F, Qiu F. Increased risk of papillary thyroid cancer related to hormonal factors in women. Tumour Biol. 2015;36:5127–5132. doi: 10.1007/s13277-015-3165-0. [DOI] [PubMed] [Google Scholar]
  • 17.Zhou B, Coorperative Meta-Analysis Group Of China Obesity Task Force Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Biomed Environ Sci. 2002;23:5–10. [PubMed] [Google Scholar]
  • 18.Xhaard C, Rubino C, Cléro E, Maillard S, Ren Y, Borson-Chazot F, et al. Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: a population-based case-control study. Am J Epidemiol. 2014;180:1007–1017. doi: 10.1093/aje/kwu220. [DOI] [PubMed] [Google Scholar]
  • 19.Caini S, Gibelli B, Palli D, Saieva C, Ruscica M, Gandini S. Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies. Cancer Causes Control. 2015;26:511–518. doi: 10.1007/s10552-015-0546-z. [DOI] [PubMed] [Google Scholar]
  • 20.Horn-Ross PL, Canchola AJ, Ma H, Reynolds P, Bernstein L. Hormonal factors and the risk of papillary thyroid cancer in the California Teachers Study cohort. Cancer Epidemiol Biomark Prev. 2011;20:1751–1759. doi: 10.1158/1055-9965.EPI-11-0381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zamora-Ros R, Rinaldi S, Biessy C, Tjønneland A, Halkjaer J, Fournier A, et al. Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer. 2015;136:1218–1227. doi: 10.1002/ijc.29067. [DOI] [PubMed] [Google Scholar]
  • 22.Cao Y, Wang Z, Gu J, Hu F, Qi Y, Yin Q, et al. Reproductive factors but not hormonal factors associated with thyroid cancer risk: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:103515. doi: 10.1155/2015/103515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kabat GC, Kim MY, Wactawski-Wende J, Lane D, Wassertheil-Smoller S, Rohan TE. Menstrual and reproductive factors, exogenous hormone use, and risk of thyroid carcinoma in postmenopausal women. Cancer Causes Control. 2012;23:2031–2040. doi: 10.1007/s10552-012-0084-x. [DOI] [PubMed] [Google Scholar]
  • 24.Shin S, Sawada N, Saito E, Yamaji T, Iwasaki M, Shimazu T, et al. Menstrual and reproductive factors in the risk of thyroid cancer in Japanese women: the Japan Public Health Center-Based Prospective Study. Eur J Cancer Prev. 2018;27:361–369. doi: 10.1097/CEJ.0000000000000338. [DOI] [PubMed] [Google Scholar]
  • 25.Cordina-Duverger E, Leux C, Neri M. Hormonal and reproductive risk factors of papillary thyroid cancer: a population-based case-control study in France. Cancer Epidemiol. 2017;48:78–84. doi: 10.1016/j.canep.2017.04.001. [DOI] [PubMed] [Google Scholar]
  • 26.Rossing MA, Voigt LF, Wicklund KG, Daling JR. Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol. 2000;151:765–772. doi: 10.1093/oxfordjournals.aje.a010276. [DOI] [PubMed] [Google Scholar]
  • 27.Glinoer D, de Nayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab. 1990;71:276–287. doi: 10.1210/jcem-71-2-276. [DOI] [PubMed] [Google Scholar]
  • 28.Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab. 2001;86:1072–1077. doi: 10.1210/jcem.86.3.7283. [DOI] [PubMed] [Google Scholar]
  • 29.Schonfeld SJ, Ron E, Kitahara CM, Brenner A, Park Y, Sigurdson AJ, et al. Hormonal and reproductive factors and risk of postmenopausal thyroid cancer in the NIH-AARP Diet and Health Study. Cancer Epidemiol. 2011;35:e85–90. doi: 10.1016/j.canep.2011.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Truong T, Orsi L, Dubourdieu D, Rougier Y, Hémon D, Guénel P. Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol. 2005;161:1056–1065. doi: 10.1093/aje/kwi136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zivaljevic V, Vlajinac H, Jankovic R, Marinkovic J, Dzodic R, Sipeti Grujii S, et al. Case-control study of female thyroid cancer–menstrual, reproductive and hormonal factors. Eur J Cancer Prev. 2003;12:63–66. doi: 10.1097/00008469-200302000-00010. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12905_2020_1160_MOESM1_ESM.docx (79.8KB, docx)

Additional file 1. The questionnaire used for this study.

12905_2020_1160_MOESM2_ESM.docx (20KB, docx)

Additional file 2: Table S1. ORs of thyroid cancer associated with menstrual, reproductive and hormonal factors, stratified by age at enrollment.

Data Availability Statement

The data can be accessed from the corresponding author upon justified request.


Articles from BMC Women's Health are provided here courtesy of BMC

RESOURCES